SPYRE THERAPEUTICS, INC. Cash and Restricted Cash
SPYRE THERAPEUTICS, INC. (SYRE) had Cash and Restricted Cash of $162.01 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Cash
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-04
- 2026-06-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $162.01M.
- 2026-03-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $97.19M.
- 2025-12-31: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $85.72M.
- 2025-09-30: Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $64.90M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
|---|---|
| 2026-06-30 | $162.01M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $97.19M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $85.72M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $64.90M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $81.66M 10-Q · filed 2026-08-04 |
| 2025-03-31 | $48.49M 10-Q · filed 2026-05-05 |
| 2024-12-31 | $89.42M 10-Q · filed 2026-08-04 |
| 2024-09-30 | $71.58M 10-Q · filed 2025-11-04 |
| 2024-06-30 | $45.47M 10-Q · filed 2025-08-05 |
| 2024-03-31 | $227.87M 10-Q · filed 2025-05-08 |
| 2023-12-31 | $189.22M 10-K · filed 2026-02-19 |
| 2023-09-30 | $91.90M 10-Q/A · filed 2024-11-18 |
| 2023-06-30 | $236.68M 10-Q/A · filed 2024-11-18 |
| 2023-03-31 | $36.55M 10-Q/A · filed 2024-11-18 |
| 2022-12-31 | $36.42M 10-K · filed 2026-02-19 |
| 2022-09-30 | $40.52M 10-Q · filed 2023-11-09 |
| 2021-12-31 | $16.98M 10-K · filed 2025-02-27 |
| 2020-12-31 | $91.94M 10-K/A · filed 2024-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |